Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021129624> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2021129624 abstract "Purpose: Brain metastases of breast cancer cause neurocognitive damage and are incurable. We evaluated in experimental brain metastasis model a role of temozolomide, an oral brain permeable alkylating agent characterized by significant uptake in the central nervous system, in the prevention of brain metastases of breast cancer. Material and methods: To assess preventive role of temozolomide, mice were inoculated with 175,000 triple-negative 231-BR-EGFP cells in 0.1 mL PBS in the left ventricle of the heart. Three days after tumor cell inoculation, mice were randomized to temozolomide at the dose of 50 mg/kg delivered by oral gavage in saline, 5 days a week for 4 weeks, or vehicle. Subsequent experiments used temozolomide doses of 25, 10, 5, 1 and 0.5 mg/kg. To evaluate the efficacy of temozolomide in treating established BM, mice received temozolomide (50 mg/kg) beginning on either day 18 or day 24 post-injection of 231-BR-EGFR cells, 5 days a week for two and one week, respectively. To investigate the impact of temozolomide on survival, mice injected with 231-BR-EGFP cells were randomized to vehicle, temozolomide on days 3-14, or temozolomide on days 17-28 post-injection, per the schedule described above. To determine the functional contribution of MGMT expression in the BM preventive model, similar experiments were performed using 231-BR-EGFP cells with induced MGMT expression, and MGMT-positive Jimt-1 cells. Metastases were counted in step sections of one hemisphere of each brain. Additionally, the percentage of MGMT-positive tumor cells in 62 patient-matched sets of breast cancer primary tumors and resected brain metastases was determined immunohistochemically. Results: Temozolomide, when dosed at 50, 25, 10 or 5 mg/kg, 5 days/week, beginning 3 days after inoculation, completely prevented the formation of experimental brain metastases from MGMT-negative 231-BR-EGFP cell line. At a 1 mg/kg dose, temozolomide prevented 68% of large brain metastases, and was ineffective at a dose of 0.5 mg/kg. When the 50 mg/kg dose was administered beginning on days 18 or 24, temozolomide efficacy was reduced or absent. Both schedules of temozolomide (days 3-14 and days 17-28) significantly increased survival (P = .0003 by long-rank test). Earlier administration of temozolomide resulted in long term survival of 6 and 2 out of 10 mice, respectively; a significant difference compared to vehicle ( P Conclusions: Temozolomide profoundly prevents the outgrowth of experimental brain metastases of breast cancer in a MGMT-dependent manner. The majority of patients had low MGMT expressing brain metastases. These data provide a compelling rationale for investigating preventive efficacy of temozolomide in high-risk advanced breast cancer patients. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-11-04." @default.
- W2021129624 created "2016-06-24" @default.
- W2021129624 creator A5003436928 @default.
- W2021129624 creator A5004874011 @default.
- W2021129624 creator A5017484722 @default.
- W2021129624 creator A5024502942 @default.
- W2021129624 creator A5034661031 @default.
- W2021129624 creator A5035731654 @default.
- W2021129624 creator A5039251639 @default.
- W2021129624 creator A5045464653 @default.
- W2021129624 creator A5069533295 @default.
- W2021129624 creator A5071802503 @default.
- W2021129624 creator A5075505236 @default.
- W2021129624 creator A5078772487 @default.
- W2021129624 creator A5089751620 @default.
- W2021129624 date "2013-12-15" @default.
- W2021129624 modified "2023-09-27" @default.
- W2021129624 title "Abstract P6-11-04: Profound prevention of experimental brain metastases of breast cancer by temozolomide in a MGMT-dependent manner" @default.
- W2021129624 doi "https://doi.org/10.1158/0008-5472.sabcs13-p6-11-04" @default.
- W2021129624 hasPublicationYear "2013" @default.
- W2021129624 type Work @default.
- W2021129624 sameAs 2021129624 @default.
- W2021129624 citedByCount "0" @default.
- W2021129624 crossrefType "proceedings-article" @default.
- W2021129624 hasAuthorship W2021129624A5003436928 @default.
- W2021129624 hasAuthorship W2021129624A5004874011 @default.
- W2021129624 hasAuthorship W2021129624A5017484722 @default.
- W2021129624 hasAuthorship W2021129624A5024502942 @default.
- W2021129624 hasAuthorship W2021129624A5034661031 @default.
- W2021129624 hasAuthorship W2021129624A5035731654 @default.
- W2021129624 hasAuthorship W2021129624A5039251639 @default.
- W2021129624 hasAuthorship W2021129624A5045464653 @default.
- W2021129624 hasAuthorship W2021129624A5069533295 @default.
- W2021129624 hasAuthorship W2021129624A5071802503 @default.
- W2021129624 hasAuthorship W2021129624A5075505236 @default.
- W2021129624 hasAuthorship W2021129624A5078772487 @default.
- W2021129624 hasAuthorship W2021129624A5089751620 @default.
- W2021129624 hasConcept C121608353 @default.
- W2021129624 hasConcept C126322002 @default.
- W2021129624 hasConcept C143998085 @default.
- W2021129624 hasConcept C2776694085 @default.
- W2021129624 hasConcept C2777389519 @default.
- W2021129624 hasConcept C2778164965 @default.
- W2021129624 hasConcept C2779013556 @default.
- W2021129624 hasConcept C2780964509 @default.
- W2021129624 hasConcept C530470458 @default.
- W2021129624 hasConcept C71924100 @default.
- W2021129624 hasConceptScore W2021129624C121608353 @default.
- W2021129624 hasConceptScore W2021129624C126322002 @default.
- W2021129624 hasConceptScore W2021129624C143998085 @default.
- W2021129624 hasConceptScore W2021129624C2776694085 @default.
- W2021129624 hasConceptScore W2021129624C2777389519 @default.
- W2021129624 hasConceptScore W2021129624C2778164965 @default.
- W2021129624 hasConceptScore W2021129624C2779013556 @default.
- W2021129624 hasConceptScore W2021129624C2780964509 @default.
- W2021129624 hasConceptScore W2021129624C530470458 @default.
- W2021129624 hasConceptScore W2021129624C71924100 @default.
- W2021129624 hasLocation W20211296241 @default.
- W2021129624 hasOpenAccess W2021129624 @default.
- W2021129624 hasPrimaryLocation W20211296241 @default.
- W2021129624 hasRelatedWork W1492510657 @default.
- W2021129624 hasRelatedWork W1517300314 @default.
- W2021129624 hasRelatedWork W1535002852 @default.
- W2021129624 hasRelatedWork W1584659596 @default.
- W2021129624 hasRelatedWork W1654031236 @default.
- W2021129624 hasRelatedWork W1768539124 @default.
- W2021129624 hasRelatedWork W1849539815 @default.
- W2021129624 hasRelatedWork W1983841743 @default.
- W2021129624 hasRelatedWork W1989071242 @default.
- W2021129624 hasRelatedWork W2067357376 @default.
- W2021129624 hasRelatedWork W2485064467 @default.
- W2021129624 hasRelatedWork W2504089630 @default.
- W2021129624 hasRelatedWork W2590559100 @default.
- W2021129624 hasRelatedWork W2734168421 @default.
- W2021129624 hasRelatedWork W2773499080 @default.
- W2021129624 hasRelatedWork W2887572314 @default.
- W2021129624 hasRelatedWork W2929211950 @default.
- W2021129624 hasRelatedWork W3122793031 @default.
- W2021129624 hasRelatedWork W3153823809 @default.
- W2021129624 hasRelatedWork W2741482625 @default.
- W2021129624 isParatext "false" @default.
- W2021129624 isRetracted "false" @default.
- W2021129624 magId "2021129624" @default.
- W2021129624 workType "article" @default.